| Name | Title | Contact Details |
|---|
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Eton is an innovative pharmaceutical company that searches the world over for meaningful therapies that we can bring to patients living with rare diseases.
Dedicated to Global Product Safety, Brand Loyalty, and Patient Access Strategies that Support the Full Product Lifecycle United BioSource LLC (UBC) is a leading provider of pharmaceutical support services, partnering with life science companies to make medicine and medical products safer and more accessible. Our diverse suite of services helps bridge the gap between development and delivery and builds brand loyalty through patient access and adherence. UBC is well known for our ability to generate authoritative, real-world evidence of product effectiveness, safety, and value to assist healthcare decisions and enhance patient care. Developing a drug, taking it through commercialization, and demonstrating its post-launch value and safety is a complex journey. Regulatory hurdles and payer decision-making are increasing the complexity around drug development and product choices. UBC has aligned our expertise and industry insight to help manufacturers make informed decisions early in the product journey that ultimately optimize care and improve patient outcomes. The most successful product journeys start with great maps. UBC`s industry-leading experts work in unison to effectively navigate the product lifecycle, focusing on: Clinical Development Safety Commercialization We understand what it takes to compete in a crowded product market with many stakeholders that demand the right evidence at the right time. Our Past, Present, and Our Future UBC was founded in 2003 by industry experts with a passion for innovation and a commitment to working with pharmaceutical and biotech organizations in proving the safety, efficacy, and value of pharmaceutical and medical products. We recognized the opportunity to build an organization tailored to meet the need for scientific evidence in the healthcare industry. And, we quickly developed our core strength – the generation, analysis, and communication of real-world evidence throughout the product lifecycle.
Low T Center, mens health clinic, offers treatment for low t levels with testosterone replacement therapy, (hormone replacement), and sleep apnea .
Pharmacosmos A/S is specialized in iron therapy. We develop, manufacture and market medicines for treatment of iron deficiency anaemia in humans and animals.